In 2023, South Korea led Global Total Intramural Expenditure on R&D in Medical and Health Sciences with $7.72 billion PPP, experiencing significant growth of 11.84% from the previous year. Taiwan's spending reached $3.2 billion, reflected in a modest 2.82% increase. Poland's substantial 13.16% rise brought its total to $2.86 billion. Other notable increases included Slovakia's 14.09% jump to $0.13853 billion, and Singapore's 7.11% enhancement to $2.52 billion. The overall five-year CAGR indicates a solid upward trend for many countries, highlighting growth focused on expanding R&D capabilities in this vital sector.
Looking ahead, countries are expected to invest heavily in digital health tech, regenerative medicines, and patient-centric innovations. Strategic partnerships and international collaborations will drive further advancements in medical sciences, ensuring robust growth and dynamic changes in global R&D priorities over the coming years.
Top countries in Total Intramural Expenditure on R&D in Medical and Health Sciences by Country
| # | 10 Countries | Million US Dollars PPP = 2015 | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 South Korea | 7,720 | 2023 | +7.24% | +11.84% | View data |
| 2 | 2 Taiwan | 3,200 | 2023 | +2.82% | +2.82% | View data |
| 3 | 3 Poland | 2,860 | 2023 | +9.82% | +13.16% | View data |
| 4 | 4 Singapore | 2,520 | 2023 | +3.63% | +7.11% | View data |
| 5 | 5 Russia | 1,740 | 2023 | +2.5% | +3.3% | View data |
| 6 | 6 Portugal | 751.65 | 2023 | +1.21% | +5.55% | View data |
| 7 | 7 Czech Republic | 486.69 | 2023 | +1.57% | -0.55% | View data |
| 8 | 8 Hungary | 315.5 | 2023 | +1.94% | +3.18% | View data |
| 9 | 9 Slovenia | 263.85 | 2023 | +2.11% | +3.64% | View data |
| 10 | 10 Chile | 202.64 | 2023 | +2.25% | +2.12% | View data |
